What did the FDA approve in August 2025?
In August 2025 the FDA approved Wegovy for MASH, making semaglutide a treatment for metabolic dysfunction-associated steatohepatitis in adults with moderate to advanced liver scarring. MASH is the inflamed form of fatty liver disease that can lead to scarring and, over time, cirrhosis. It used to be called NASH.
The Wegovy label draws the lines clearly. The liver must be noncirrhotic, the scarring must be consistent with fibrosis stage F2 to F3, and the medicine is used with a reduced-calorie diet and more activity. The label’s maintenance dose for this use is 2.4 mg weekly, with 1.7 mg as a fallback when 2.4 mg is not tolerated. These are context only; your provider sets the dose.
This was an accelerated approval. The decision rested on biopsy changes, a surrogate measure, rather than on fewer cases of liver failure, transplant or death. The trial is set to run 240 weeks to answer that bigger question, and continued approval depends on it.
How well did semaglutide work in the trial?
The interim analysis looked at the first 800 of 1,197 patients in the phase 3 trial published in 2025, each with a liver biopsy at the start and again at week 72.
| Week 72 result | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| MASH resolved, scarring no worse | 63% | 34% |
| Scarring improved one stage or more, MASH no worse | 37% | 22% |
| Both MASH resolved and scarring improved | 33% | 16% |
| Average change in body weight | -10.5% | -2.0% |
Placebo patients did better than many people expect, which is a reminder that lifestyle counseling counts too. Still, more than a third of the semaglutide group did not reach the first goal, so this is a strong option, not a sure thing.
Does it help ordinary fatty liver too?
Not as an approved use. Many men hear “fatty liver” after an ultrasound or a mildly high ALT, which shows fat in the liver but says nothing about inflammation or scarring. The MASH approval only applies once scarring at stage F2 to F3 is established.
Staging does not have to start with a needle. The NIDDK explains that routine blood results can be turned into scores such as FIB-4 or APRI to help rule advanced fibrosis in or out, that elastography measures liver stiffness, and that a liver biopsy is the only test that proves NASH and shows its severity.
For a man with obesity and a fatty liver but no significant scarring, semaglutide may still come up under its weight-management approval. Weight loss itself matters here: in a controlled study of graded weight loss, liver fat changed step by step as people lost about 5, 11 and 16 percent of their weight, and liver insulin sensitivity improved at the first 5 percent.
Which liver labs are tracked on treatment?
ALT and AST are the two numbers you will see most. In the trial, the label reports a trend of greater drops in average ALT and AST with semaglutide than with placebo starting at week 12 and continuing through week 72. MedlinePlus notes that liver function tests are used to monitor liver disease over time and to see how well treatment is working, and that abnormal results usually need other tests to pin down the cause.
| Lab | What it tells your provider |
|---|---|
| ALT and AST | Liver cell irritation; expected to drift down if liver fat falls |
| Platelets with ALT, AST and age | Inputs for a FIB-4 fibrosis score |
| Bilirubin and alkaline phosphatase | Bile flow, useful because gallbladder problems are more common on GLP-1 medicines |
| Lipase | Pancreas enzyme; rose above three times normal in 4.7% on semaglutide vs 1.3% on placebo in the MASH trial, with unclear meaning unless symptoms appear |
| A1C and lipids | The metabolic drivers behind fatty liver |
Our page on ALT and AST liver enzymes explains what raises each one, including hard lifting and supplements.
Is it safe if my liver is already scarred?
The approval stops short of cirrhosis, so men with cirrhosis are outside it. Within the MASH trial, side effects looked like those seen in the weight trials, led by nausea and other stomach effects. The label also lists fractures in 4.4% of semaglutide patients versus 3.3% on placebo in that trial, which is worth knowing if you are older or have thin bones.
For the bigger picture on causes, alcohol limits and long-term risk, see fatty liver disease in men, and for how the medicine works in general, our semaglutide medication guide.
How Ultimate Male handles a fatty liver result
At our San Gabriel and Downey clinics, a fatty liver finding is read as part of the whole metabolic picture. The liver and kidney function panel is drawn on site, results come back in 24 to 48 hours, and a PA-C or MD reviews ALT, AST, platelets, A1C and lipids with you, along with alcohol, supplements and medicines that can raise liver enzymes.
If your numbers point toward MASH with scarring, staging usually involves elastography or a liver specialist, and the clinic can coordinate a medical weight loss plan that runs alongside that care. If the liver fat is uncomplicated, the conversation shifts to how much weight loss would help and whether a GLP-1 medicine fits at all. A free 10-minute call at 626-319-5261 is the place to start.
